We evaluated the impact of opioid substitution therapy (OST) on the completion, adherence, efficacy, and safety of the 3-direct-acting antiviral regimen of ombitasvir, paritaprevir (identified by AbbVie and Enanta) co-dosed with ritonavir, and dasabuvir ± ribavirin among patients infected with hepatitis C virus (HCV) genotype (GT) 1, with or without compensated cirrhosis.
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials / Grebely, Jason; Puoti, Massimo; Wedemeyer, Heiner; Cooper, Curtis; Sulkowski, Mark S; Foster, Graham R; Berg, Thomas; Villa, Erica; Rodriguez-Perez, Federico; Wyles, David L; Schnell, Gretja; Alami, Negar N; Zhang, Zhenzhen; Dumas, Emily; Dore, Gregory J. - In: OPEN FORUM INFECTIOUS DISEASES. - ISSN 2328-8957. - 5:11(2018), pp. ofy248-ofy248. [10.1093/ofid/ofy248]
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials
Villa, Erica;
2018
Abstract
We evaluated the impact of opioid substitution therapy (OST) on the completion, adherence, efficacy, and safety of the 3-direct-acting antiviral regimen of ombitasvir, paritaprevir (identified by AbbVie and Enanta) co-dosed with ritonavir, and dasabuvir ± ribavirin among patients infected with hepatitis C virus (HCV) genotype (GT) 1, with or without compensated cirrhosis.
| File | Dimensione | Formato | |
|---|---|---|---|
|
ofy248.pdf
Open access
Tipologia:
VOR - Versione pubblicata dall'editore
Dimensione
194.8 kB
Formato
Adobe PDF
|
194.8 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
